SG11202001377PA - Bisamide sarcomere activating compounds and uses thereof - Google Patents
Bisamide sarcomere activating compounds and uses thereofInfo
- Publication number
- SG11202001377PA SG11202001377PA SG11202001377PA SG11202001377PA SG11202001377PA SG 11202001377P A SG11202001377P A SG 11202001377PA SG 11202001377P A SG11202001377P A SG 11202001377PA SG 11202001377P A SG11202001377P A SG 11202001377PA SG 11202001377P A SG11202001377P A SG 11202001377PA
- Authority
- SG
- Singapore
- Prior art keywords
- bisamide
- activating compounds
- sarcomere
- sarcomere activating
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762557846P | 2017-09-13 | 2017-09-13 | |
| PCT/US2018/050793 WO2019055590A1 (en) | 2017-09-13 | 2018-09-13 | SARCOMERIC BISAMIDE ACTIVATOR COMPOUNDS AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001377PA true SG11202001377PA (en) | 2020-03-30 |
Family
ID=63794635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001377PA SG11202001377PA (en) | 2017-09-13 | 2018-09-13 | Bisamide sarcomere activating compounds and uses thereof |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US10723720B2 (https=) |
| EP (1) | EP3681882A1 (https=) |
| JP (1) | JP7308816B2 (https=) |
| KR (1) | KR20200054237A (https=) |
| CN (1) | CN111601798B (https=) |
| AR (1) | AR112804A1 (https=) |
| AU (1) | AU2018332887B2 (https=) |
| BR (1) | BR112020004800A2 (https=) |
| CA (1) | CA3075669A1 (https=) |
| CL (1) | CL2020000610A1 (https=) |
| CO (1) | CO2020002745A2 (https=) |
| CR (1) | CR20200116A (https=) |
| EA (1) | EA202090688A1 (https=) |
| IL (1) | IL272573B2 (https=) |
| JO (1) | JOP20200059A1 (https=) |
| MA (1) | MA50173A (https=) |
| MX (2) | MX2020002696A (https=) |
| PE (1) | PE20200924A1 (https=) |
| PH (1) | PH12020500446A1 (https=) |
| SA (1) | SA520411524B1 (https=) |
| SG (1) | SG11202001377PA (https=) |
| TW (1) | TWI790281B (https=) |
| UY (1) | UY37879A (https=) |
| WO (1) | WO2019055590A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20200924A1 (es) | 2017-09-13 | 2020-09-14 | Amgen Inc | Compuestos de bisamida sustituida que activan el sarcomero cardiaco |
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| IL311042B1 (en) * | 2018-05-29 | 2026-04-01 | Omeros Corp | MASP-2 inhibitors and methods of use |
| US20220185791A1 (en) * | 2019-03-12 | 2022-06-16 | Amgen Inc. | Polymorphs of a cardiac troponin activator |
| SG11202109891WA (en) * | 2019-03-12 | 2021-10-28 | Amgen Inc | Polymorphs and cocrystals of a cardiac troponin activator |
| CN118561817A (zh) * | 2019-07-23 | 2024-08-30 | ๆ่ณๅ ฌๅธ | ไฝไธบๅ่ฏ็ๆฐ็ๆ่ณๅบ-ไธๅๅๅ็ฉ |
| EP4069676A1 (en) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| IL293588B1 (en) | 2019-12-04 | 2026-04-01 | Omeros Corp | 3-Amino-1-methylpyrazin-2(H1)-one derivatives as MASP-2 inhibitors, compositions containing them and uses thereof |
| BR112022010895A2 (pt) | 2019-12-04 | 2022-09-06 | Omeros Corp | Composto, composiรงรฃo farmacรชutica, e, mรฉtodo para tratar uma doenรงa ou distรบrbio associado ร serina protease-2 associada ร lectina de ligaรงรฃo ao manan |
| EP4069678A1 (en) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| US11802122B2 (en) * | 2020-06-17 | 2023-10-31 | Merck Sharp & Dohme Llc | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors |
| AU2022239717A1 (en) | 2021-03-15 | 2023-11-02 | Maze Therapeutics, Inc. | Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof |
| WO2023122325A2 (en) * | 2021-12-23 | 2023-06-29 | Regents Of The University Of Michigan | Meta anilide compounds and methods for use of the same to treat diseases and disorders |
| JP2025534288A (ja) | 2022-09-26 | 2025-10-15 | ใจใใธใฏใคใบ ใปใฉใใฅใผใใฃใฏใน๏ผ ใคใณใณใผใใฌใคใใใ | ๏ผ๏ผ๏ผ๏ผใธใใใญใญใใพใชใใณๅๅ็ฉใใใณใใฎไฝฟ็จ |
| WO2024206339A1 (en) | 2023-03-27 | 2024-10-03 | Edgewise Therapeutics, Inc. | Quinolinone amide compounds and uses thereof |
| EP4688756A1 (en) | 2023-03-27 | 2026-02-11 | Edgewise Therapeutics, Inc. | Quinazoline dione compounds and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0662529B2 (ja) * | 1984-07-13 | 1994-08-17 | ไธๅ ฑๆ ชๅผไผ็คพ | ใขใใ้ ธ่ชๅฐไฝ |
| US5952307A (en) | 1994-01-21 | 1999-09-14 | Georgia Tech Research Corp. | Basic ฮฑ-aminoalkylphosphonate derivatives |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| GB9708119D0 (en) | 1997-04-22 | 1997-06-11 | Glaxo Group Ltd | Chemical compounds |
| WO2001029062A2 (en) | 1999-10-18 | 2001-04-26 | University Technology Corporation | Method for modulation of cell phenotype |
| WO2001054503A1 (en) | 2000-01-28 | 2001-08-02 | Akkadix Corporation | Methods for killing nematodes and nematode eggs using 4-phenoxy-6-aminopyrimidine derivatives |
| EP1125925A1 (en) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
| US6495337B1 (en) | 2000-03-29 | 2002-12-17 | Cytokinetics, Inc. | High throughput sarcomeric assay |
| JP2004528822A (ja) | 2000-11-07 | 2004-09-24 | ใใผใใปใชใใปใชใผใธใงใณใ๏ผใถใปใฆใใดใกใผใทใใฃใปใชใดใปใใญใตในใปใทในใใ | ็ญ็น็ฐ็็ญ็ฏใซใซใทใใฅใผใชใณ็ตๅใฟใณใใฏ่ณช๏ผใซใซใตใซใทใณ๏ผใซ้ขใใๆนๆณใใใณ็ตๆ็ฉ |
| US6908923B2 (en) | 2001-12-21 | 2005-06-21 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| AU2002365057A1 (en) | 2001-12-21 | 2003-07-30 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| ATE552236T1 (de) | 2003-01-14 | 2012-04-15 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz |
| EP1605752B1 (en) | 2003-03-27 | 2011-09-14 | Cytokinetics, Inc. | Sulfonamides for the treatment of congestive heart failure, their compositions and uses. |
| US20050043260A1 (en) | 2003-04-21 | 2005-02-24 | Baylor College Of Medicine | Wnt as a factor for cardiac myogenesis |
| US7541466B2 (en) | 2003-12-23 | 2009-06-02 | Genzyme Corporation | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases |
| JP2005298628A (ja) | 2004-04-09 | 2005-10-27 | Sumitomo Chemical Co Ltd | ใชใฌใใฃใณ้ๅ่งฆๅชๆๅๅใณใชใฌใใฃใณ้ๅไฝใฎ่ฃฝ้ ๆนๆณ |
| ES2522579T3 (es) | 2004-06-17 | 2014-11-17 | Cytokinetics, Inc. | Compuestos, composiciones y mรฉtodos |
| US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
| ES2419007T3 (es) | 2005-12-15 | 2013-08-19 | Cytokinetics, Inc. | Ciertas entidades quรญmicas, composiciones y procedimientos |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| US20070208000A1 (en) | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
| WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| WO2007078839A2 (en) | 2005-12-19 | 2007-07-12 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2007089805A2 (en) | 2006-01-31 | 2007-08-09 | The General Hospital Corporation | Anti-hypertrophic effects and inotropic effects of picot |
| US20080227823A1 (en) | 2007-03-12 | 2008-09-18 | Hassan Pajouhesh | Amide derivatives as calcium channel blockers |
| GB0708818D0 (en) | 2007-05-08 | 2007-06-13 | Portela & Ca Sa | Compounds |
| US20090192168A1 (en) | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| WO2013059278A2 (en) | 2011-10-17 | 2013-04-25 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| KR102668696B1 (ko) * | 2012-01-12 | 2024-05-29 | ์์ผ ์ ๋๋ฒ์ํฐ | E3 ์ ๋นํดํด ๋ฆฌ๊ฐ์์ ์ ์ํ ํ์ ๋จ๋ฐฑ์ง ๋ฐ ๋ค๋ฅธ ํด๋ฆฌํฉํฐ๋์ ์ฆ์ง๋ ๋ถํด๋ฅผ ์ํ ํํฉ๋ฌผ ๋ฐ ๋ฐฉ๋ฒ |
| WO2013106646A2 (en) | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| US9895308B2 (en) | 2013-03-14 | 2018-02-20 | Amgen Inc. | Heterocyclic compounds and their uses |
| WO2015103527A1 (en) | 2014-01-06 | 2015-07-09 | The Scripps Research Institute | Modulators of rev-erb |
| WO2015142001A2 (ko) | 2014-03-21 | 2015-09-24 | ์ถฉ๋จ๋ํ๊ต์ฐํํ๋ ฅ๋จ | ๊ฐ์ฌ ํ์ฑ์ ๊ฐ๋ ํํฉ๋ฌผ ๋ฐ ์ด๋ฅผ ํจ์ ํ๋ ์ฌ๋ถ์ ์๋ฐฉ ๋๋ ์น๋ฃ์ฉ ์ฝํ์ ์กฐ์ฑ๋ฌผ |
| EP4234017B1 (en) | 2015-01-22 | 2026-04-15 | MyoKardia, Inc. | Preparation of 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm) |
| EP3270917A4 (en) | 2015-03-18 | 2018-08-08 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| US10829440B2 (en) | 2015-06-12 | 2020-11-10 | Brown University | Antibacterial compounds and methods of making and using same |
| KR101766731B1 (ko) | 2015-06-23 | 2017-08-10 | ์ถฉ๋จ๋ํ๊ต์ฐํํ๋ ฅ๋จ | ๊ฐ์ฌ ํ์ฑ์ ๊ฐ๋ ํฌ๋ก๋ฉ๋ ผ ์ ๋์ฒด ๋ฐ ์ด๋ฅผ ํฌํจํ๋ ์ฌ๋ถ์ ์ ์๋ฐฉ ๋๋ ์น๋ฃ์ฉ ์ฝํ ์กฐ์ฑ๋ฌผ |
| US10543215B2 (en) | 2015-06-26 | 2020-01-28 | Amgen Inc. | Combination therapy of cardiac myosin activator and sinus node if current inhibitor |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos mรฉdicos |
| KR20160108281A (ko) | 2016-09-06 | 2016-09-19 | ์ถฉ๋จ๋ํ๊ต์ฐํํ๋ ฅ๋จ | ๊ฐ์ฌ ํ์ฑ์ ๊ฐ๋ ํํฉ๋ฌผ ๋ฐ ์ด๋ฅผ ํจ์ ํ๋ ์ฌ๋ถ์ ์๋ฐฉ ๋๋ ์น๋ฃ์ฉ ์ฝํ์ ์กฐ์ฑ๋ฌผ |
| AU2018294254C1 (en) | 2017-06-30 | 2022-10-13 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| PE20200924A1 (es) | 2017-09-13 | 2020-09-14 | Amgen Inc | Compuestos de bisamida sustituida que activan el sarcomero cardiaco |
| PT3594199T (pt) | 2018-07-09 | 2020-09-04 | Amgen Inc | 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparaรงรฃo |
| MA53226A (fr) | 2018-08-17 | 2021-11-24 | Amgen Inc | Sel et formes cristallines d'omecamtiv mecarbil |
| WO2020131574A1 (en) | 2018-12-18 | 2020-06-25 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| US20220185791A1 (en) | 2019-03-12 | 2022-06-16 | Amgen Inc. | Polymorphs of a cardiac troponin activator |
| SG11202109891WA (en) | 2019-03-12 | 2021-10-28 | Amgen Inc | Polymorphs and cocrystals of a cardiac troponin activator |
-
2018
- 2018-09-13 PE PE2020000339A patent/PE20200924A1/es unknown
- 2018-09-13 MA MA050173A patent/MA50173A/fr unknown
- 2018-09-13 CA CA3075669A patent/CA3075669A1/en active Pending
- 2018-09-13 US US16/129,862 patent/US10723720B2/en active Active
- 2018-09-13 AR ARP180102603A patent/AR112804A1/es unknown
- 2018-09-13 IL IL272573A patent/IL272573B2/en unknown
- 2018-09-13 CR CR20200116A patent/CR20200116A/es unknown
- 2018-09-13 BR BR112020004800-3A patent/BR112020004800A2/pt not_active Application Discontinuation
- 2018-09-13 EA EA202090688A patent/EA202090688A1/ru unknown
- 2018-09-13 CN CN201880072907.5A patent/CN111601798B/zh active Active
- 2018-09-13 UY UY0001037879A patent/UY37879A/es not_active Application Discontinuation
- 2018-09-13 TW TW107132171A patent/TWI790281B/zh active
- 2018-09-13 JO JOP/2020/0059A patent/JOP20200059A1/ar unknown
- 2018-09-13 MX MX2020002696A patent/MX2020002696A/es unknown
- 2018-09-13 WO PCT/US2018/050793 patent/WO2019055590A1/en not_active Ceased
- 2018-09-13 JP JP2020514579A patent/JP7308816B2/ja active Active
- 2018-09-13 KR KR1020207010115A patent/KR20200054237A/ko not_active Abandoned
- 2018-09-13 SG SG11202001377PA patent/SG11202001377PA/en unknown
- 2018-09-13 AU AU2018332887A patent/AU2018332887B2/en not_active Ceased
- 2018-09-13 EP EP18783202.7A patent/EP3681882A1/en not_active Withdrawn
-
2020
- 2020-03-05 PH PH12020500446A patent/PH12020500446A1/en unknown
- 2020-03-10 CO CONC2020/0002745A patent/CO2020002745A2/es unknown
- 2020-03-10 CL CL2020000610A patent/CL2020000610A1/es unknown
- 2020-03-10 MX MX2022014864A patent/MX2022014864A/es unknown
- 2020-03-12 SA SA520411524A patent/SA520411524B1/ar unknown
- 2020-03-27 US US16/833,321 patent/US11254658B2/en not_active Expired - Fee Related
- 2020-03-27 US US16/833,336 patent/US10899746B2/en active Active
- 2020-10-12 US US17/068,518 patent/US11299479B1/en active Active
-
2022
- 2022-02-15 US US17/672,594 patent/US11780826B2/en active Active
-
2023
- 2023-08-17 US US18/451,757 patent/US20240158372A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272573A (en) | Sarcomere activating bisamide compounds and their uses | |
| IL273236A (en) | Pyrazolopyrimidine compounds and their uses | |
| GB201708652D0 (en) | Novel compounds and uses | |
| GB201714745D0 (en) | New compounds and uses | |
| IL277502A (en) | Compounds and uses for them | |
| GB201714734D0 (en) | New compounds and uses | |
| IL272808B (en) | Pyridineamine-pyridone and pyrimidineamine-pyridone compounds | |
| GB201714740D0 (en) | New compounds and uses | |
| GB201616439D0 (en) | Compounds and uses | |
| IL267626B1 (en) | Teraaryl compounds and their uses | |
| IL265531A (en) | N 3 -cyclically substituted thienouraciles and use thereof | |
| IL269836B (en) | Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use | |
| IL267937A (en) | Amide compounds and their use | |
| IL279483A (en) | Cyanotriazole compounds and their uses | |
| IL292482B2 (en) | Azaindolylpyridone and diazaindolylpyridone compounds | |
| GB201714736D0 (en) | New compounds and uses | |
| GB202004930D0 (en) | Composition and uses thereof | |
| SG11201912432VA (en) | Emm-23 materials and processes and uses thereof | |
| GB201712110D0 (en) | New compounds and uses | |
| GB201700404D0 (en) | Compounds and composistions | |
| IL275211A (en) | Fast and flexible segment chains - division | |
| GB201614224D0 (en) | Compounds and uses thereof | |
| IL269843B (en) | Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use | |
| SG11202005282VA (en) | Emm-31 materials and processes and uses thereof | |
| HK40033831A (en) | Bisamide sarcomere activating compounds and uses thereof |